Leap Completes $51.8 Million Follow-On Offering

Healthcare

Leap follow-on offering


Summary

Leap Therapeutics, Inc. (“Leap”) (NASDAQ-GM:LPTX) recently completed an underwritten public offering of 25,875,000 shares of its common stock and pre-funded warrants, which included the exercise in full by the underwriters of their option to purchase an additional 3,375,000 shares of common stock. The gross proceeds to Leap from the offering are expected to be approximately $51.8 million.

Baird served as lead manager on this offering.

About

Leap is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic and prostate cancers. Leap has formed a partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia and New Zealand. Leap Therapeutics, Inc. is headquartered in Cambridge, Massachusetts.
CONTACT US TO LEARN MORE
Healthcare

Leap follow-on offering

Date
June 2020
Company
Leap Therapeutics, Inc.
Transaction
Equity Capital Markets
Sectors
Healthcare
Verticals
Biotechnology & Pharmaceuticals
Target Geography
North America

Share